More on Pharmacyclics (PCYC): FQ2 beats on both sales and EPS expectations. Revenue for the quarter consisted primarily of $50M in milestone revenue due to hitting a clinical milestone in connection with it's collaboration and license agreement with Janssen Biotech, plus $5M of license revenue related to its license agreement with Novo Nordisk under which Novo acquired exclusive worldwide rights to its small molecule Factor VIIa inhibitor, PCI-27483, for a restricted disease indication outside of oncology.
More on Pharmacyclics (PCYC): FQ2 beats on both sales and EPS expectations. Revenue for the...
From other sites
at CNBC.com (Jan 13, 2015)
at CNBC.com (Dec 5, 2014)
at CNBC.com (Sep 17, 2014)
at CNBC.com (Jul 29, 2014)
at CNBC.com (Jul 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs